Response Comes of Age in Chronic Lymphocytic Leukemia
The dramatically increasing knowledge about pathogenesis, genetic drivers and resistance mechanisms as well as the availability of targeted agents in all lines of therapy have major impact on the complexity of CLL management. Although we have gained a wealth of knowledge from recent advances in the genomic characterization of cancer, the linking of genetic features of individual cancers with their phenotype has been thus far largely lacking.
Dr. Cathy Wu will present recent integrative analyses of genetic data, clinical information, and growth dynamics of CLL. These studies provide a conceptual and quantitative framework of cancer growth observed directly from human patients, which provides understanding of the vast variation in the clinical behavior of CLL. In parallel to the increasing knowledge of genetic features initial therapy of CLL has changed dramatically over the past few years with introduction of targeted therapies for this disease. Definitive trials of targeted agents versus chemoimmunotherapy have solidified targeted therapies as standard of care for most patients with treatment-naïve disease.
During her talk, Dr. Jennifer Woyach will discuss the Phase III trials that have led to the current standard of care in this disease as well as ongoing studies that are poised to take initial treatment of CLL to the next level. Continuous treatment versus fixed duration therapy of monotherapies and combinations of targeted agents are treatment options in relapsed CLL.
Dr. Barbara Eichhorst will discuss during her talk the pros and cons of different treatment options by highlighting the aspects of undetectable minimal residual disease and discontinuation of therapy.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members